SEC Form 4	
------------	--

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burder hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre Jones David	ss of Reporting Perso Scott	on*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>EyePoint Pharmaceuticals, Inc.</u> [ EYPT ]	(Check	tionship of Reporting Pers all applicable) Director Officer (give title	on(s) to Issuer 10% Owner Other (specify
	(Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET		3. Date of Earliest Transaction (Month/Day/Year) 02/09/2023	X	below) SVP & Chief Comme	below)
(Street) WATERTOWN (City)	MA (State)	02472 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Filing Form filed by One Repo Form filed by More than Person	orting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)	
Common Stock	02/09/2023		М		4,967	A	\$0.00	23,089 <sup>(1)</sup>	D		
Common Stock	02/09/2023		М		5,000	A	\$0.00	28,089	D		
Common Stock	02/09/2023		F		1,483	D	<b>\$4.17</b> <sup>(2)</sup>	26,606	D		
Common Stock	02/09/2023		F		1,473	D	<b>\$4.17</b> <sup>(2)</sup>	25,133	D		

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

						·		<u> </u>	·						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year) Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	\$0.00	02/09/2023		М			5,000	(3)	(3)	Common Stock	5,000	\$0.00	10,000	D	
Restricted Stock Units	\$0.00	02/09/2023		М			4,967	(4)	(4)	Common Stock	4,967	\$0.00	4,967	D	

#### Explanation of Responses:

1. Includes 825 shares acquired on July 31, 2022 and 1,698 shares acquired on January 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

2. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.

3. The restricted stock units vest in three annual installments beginning February 9, 2023.

4. The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

### Remarks:

<u>/s/ Ron Honig, Attorney-in-</u>	/s/	Ron	Honig,	Attorney	-in-
------------------------------------	-----	-----	--------	----------	------

Fact

02/13/2023 Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.